ライフサイエンスコーパス: B virus

1 ct schedule and before exposure to hepatitis B virus.

2 ide broad protection against influenza A and B viruses.

3 ith F proteins from both RSV subgroups A and B viruses.

4 a A viruses and stalk domains from influenza B viruses.

5 from lethal challenge with diverse influenza B viruses.

6 c host restriction factor of influenza A and B viruses.

7 Liat test were 100% for both influenza A and B viruses.

8 ho were subsequently infected with influenza B virus after a mean interval of 50 days.

9 ation tests for detection of influenza A and B viruses (Alere i [Alere] and cobas Liat [Roche Diagnos

10 The study of hepatitis B virus and development of curative antivirals are hampe

11 longer term through the control of hepatitis B virus and hepatitis C virus infections by vaccination

12 ctors [screening tests looking for hepatitis B virus and hepatitis C virus status and latent tubercul

13 ica for HIV and southeast Asia for hepatitis B virus and hepatitis C virus).

14 We analyzed changes in hepatitis B virus and hepatitis delta virus (HDV) viral loads (VL)

15 haring the same envelope proteins, hepatitis B virus and hepatitis delta virus use the sodium/tauroch

16 Ultimately, these differences between B virus and HSV-1 and -2 may provide insight into the ne

17 We also confirm suppression of hepatitis B virus and poliovirus by ARB.

18 monkey virus), two hepadnaviruses (hepatitis B virus and woodchuck hepatitis virus), and an intron-re

19 cting resistance are mainly based on subtype B viruses and may under- or overestimate drug resistance

20 l activity of TRIM56 against influenza A and B viruses and provide insights into the mechanism by whi

21 Influenza A and B viruses and respiratory syncytial virus (RSV) are thre

22 the Enigma MiniLab assay for influenza A and B viruses and respiratory syncytial virus (RSV) was comp

23 riability within and between RSV group A and B viruses and the ability of multiple clades and sub-cla

24 for significant disease in humans (hepatitis B virus) and have been reported from a diverse range of

25 % for influenza A virus, 98.0% for influenza B virus, and 97.7% for RSV.

26 t (diphtheria, tetanus, pertussis, hepatitis B virus, and Haemophilus influenzae type b), yellow feve

27 studies of the prevalence of HIV, hepatitis B virus, and hepatitis C virus in people with serious me

28 C virus with and without alcohol, hepatitis B virus, and hepatocellular carcinoma (group III).

29 rus, human immunodeficiency virus, hepatitis B virus, and neonatal herpes simplex virus, from which l

30 es replication of an HBx-deficient hepatitis B virus, and rescues wild-type hepatitis B virus in a DD

31 t agreement for influenza A virus, influenza B virus, and RSV were 79.2% (95% confidence interval [95

32 nfluenza virus infections are caused by type B viruses, and these infections can be severe, especiall

33 art transplantation worldwide, and coxsackie B viruses are detected in about one-third of idiopathic

34 Influenza B viruses are important human pathogens that remain inad

35 against primary infecting and tier 1 subtype B viruses are more susceptible to superinfection.IMPORTA

36 Influenza A and B viruses are one of the most common causes of respirato

37 Influenza A and B viruses are the causative agents of annual influenza e

38 The influenza A and B viruses are the primary cause of seasonal flu epidemic

39 ection of seasonal H1N1pdm09, H3N2, and type B viruses, as well as highly pathogenic H5 and H7 viruse

40 ity and in vivo protection against influenza B viruses belonging to both haemagglutinin lineages and

41 t cell-culture and patient-derived hepatitis B virus can establish persistent infection for over 30 d

42 t consecutive infection with influenza A and B viruses can occur during a regular influenza season in

43 Chronic hepatitis B virus carriers are at risk of developing fibrosis, cir

44 B virus causes brainstem destruction in infected humans

45 Hepatitis B virus causes chronic infections in 250 million people

46 gether with the influenza A virus, influenza B virus causes seasonal flu epidemics.

47 Molecular mechanisms of B virus cell entry are poorly understood for both macaqu

48 Similar to a B virus lab strain, B virus clinical strains can effectively use both nectin

49 resistant B78H1 cells became susceptible to B virus clinical strains upon expression of either human

50 hepatitis B: infectious transgenic hepatitis B virus composed of a complete virus plus a foreign gene

51 yield and economical production of Hepatitis B Virus core (HBc) particles.

52 ed with a similar modest change in hepatitis B virus core antigen polypeptide (HBcAg/p21) synthesis,

53 Hepatitis B virus core protein has multiple roles in the viral lif

54 biomarkers toward better defining hepatitis B virus cure should occur in parallel with development o

55 ly be needed to achieve functional hepatitis B virus cure.

56 F) and functions as a receptor for coxsackie B viruses (CVBs).

57 The hepatitis B virus deploys the hepatitis B virus X protein (HBx) as

58 The Pol of duck hepatitis B virus (DHBV) also localized to the mitochondria.

59 ed assay for the detection of duck hepatitis B virus (DHBV) cccDNA and HBV nuclear DNA in established

60 For the avian hepadnavirus duck hepatitis B virus (DHBV), CTD is dephosphorylated subsequently to

61 er according to the VR definition (hepatitis B virus DNA <200, < 2000, < 20,000 IU/mL) or duration of

62 The peak levels of hepatitis B virus DNA and hepatitis B core-related antigen after c

63 Rebound of hepatitis B virus DNA and hepatitis B core-related antigen was ass

64 CHB patients with detectable serum hepatitis B virus DNA in European tertiary referral centers.

65 aminotransferase and 37% had >/=1 hepatitis B virus DNA level assessed annually.

66 anine aminotransferase and 44% had hepatitis B virus DNA testing; hepatitis B e antigen and hepatitis

67 ovide insight into the neuropathogenicity of B virus during zoonotic infections.

68 Influenza B virus encodes non-structural protein 1 (NS1B) that bin

69 Hepatitis B virus encodes the regulatory HBx protein whose primary

70 including HIV, hepatitis C virus, hepatitis B virus, enterovirus 71, influenza virus, respiratory sy

71 e cells, indicating that the nectin-mediated B virus entry depends on gD.

72 that human nectin-2 is a target receptor for B virus entry, in addition to the reported receptor huma

73 New inhibitors of hepatitis B virus entry, replication, assembly, or secretion and i

74 on microscopy (cryo-EM) structure of a clade B virus Env, which lacks only the cytoplasmic tail and i

75 management for occupational HIV or hepatitis B virus exposures includes postexposure prophylaxis (PEP

76 rus infection, and a gD-negative recombinant B virus failed to enter these cells, indicating that the

77 We developed a single-reaction influenza A/B virus (FluA/B) multiplex reverse transcription-PCR (RT

78 and matrix [M]) of seasonal influenza A and B viruses for next-generation sequencing, regardless of

79 Based on the model of the B virus gD-HVEM interface, we predict that residues R7,

80 Computational homology-based modeling of the B virus gD-nectin-1 complex revealed conformational diff

81 the inhibition to allow productive hepatitis B virus gene expression.

82 extrachromosomal reporters and the hepatitis B virus genome, suggesting a direct mechanism of transcr

83 dies against the haemagglutinin of influenza B viruses have been described, none targeting the neuram

84 pe C virus as compared to those with subtype B virus (hazard ratio [HR], 1.86; 95% confidence interva

85 HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) among PWID.

86 Advances in therapy for hepatitis B virus (HBV) and hepatitis C virus (HCV) have ushered i

87 Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection prom

88 challenges to the burden posed by hepatitis B virus (HBV) and hepatitis C virus (HCV), to learn from

89 Infections with the human hepatitis B virus (HBV) and hepatitis D virus (HDV) depend on spec

90 displays excellent potency against hepatitis B virus (HBV) and varicella-zoster virus (VZV).

91 We investigated hepatitis B virus (HBV) antibodies and galactomannan enzyme immuno

92 Outcomes of chronic infection with hepatitis B virus (HBV) are varied, with increased morbidity repor

93 rast to horizontal transmission of hepatitis B virus (HBV) between adults, which often leads to self-

94 e 1 (PRMT1) only modestly increase hepatitis B virus (HBV) biosynthesis.

95 Cell culture (cc)-derived hepatitis B virus (HBV) can infect differentiated HepaRG cells, bu

96 to track the assembly of the T = 4 hepatitis B virus (HBV) capsid in real time.

97 alyze in real time the assembly of Hepatitis B Virus (HBV) capsids below the pseudocritical concentra

98 The hepatitis B virus (HBV) causes acute and chronic liver infection,

99 Hepatitis B virus (HBV) chronic infection affects up to 240 millio

100 Hepatitis B virus (HBV) chronically infects 250 million people wor

101 were developed in patients with no Hepatitis B virus (HBV) cirrhosis (CANONIC study).

102 infected patients with and without hepatitis B virus (HBV) coinfection on antiretroviral therapy (ART

103 HDV requires a hepatitis B virus (HBV) coinfection to provide HDV with HBV surfac

104 Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serological profi

105 of the C-terminal domain (CTD) of hepatitis B virus (HBV) core or capsid protein is highly dynamic a

106 Mutations in the hepatitis B virus (HBV) core promoter (CP) have been shown to be a

107 Multiple subunits of the hepatitis B virus (HBV) core protein (HBc) assemble into an icosah

108 Though the hepatitis B virus (HBV) core protein is an important participant i

109 Hepatitis B virus (HBV) covalently closed circular (CCC) DNA funct

110 he factors involved.IMPORTANCE The hepatitis B virus (HBV) covalently closed circular (CCC) DNA, by s

111 Currently in vitro infection with hepatitis B virus (HBV) depends on cell culture-derived HBV inocul

112 Serum levels of hepatitis B virus (HBV) DNA (</=2000 IU/mL) and hepatitis B surfac

113 EC deaminases as enzymes targeting hepatitis B virus (HBV) DNA in the nucleus thus affecting its pers

114 s(t)ide analogues (NAs) suppresses hepatitis B virus (HBV) DNA production but does not affect the syn

115 hepatitis B involve suppression of hepatitis B virus (HBV) DNA with the use of nucleoside analogues.

116 %, 100%, and 100% had undetectable hepatitis B virus (HBV) DNA, respectively.

117 , 39 (72%) patients had detectable hepatitis B virus (HBV) DNA, with a median of 4.5 log copies/mL.

118 The management of hepatitis B virus (HBV) e antigen-positive viremic patients with n

119 Hepatitis B virus (HBV) encodes a multifunction reverse transcript

120 To evaluate how hepatitis B virus (HBV) genetic variation affected progression fro

121 Hepatitis B virus (HBV) genotype and its role in disease progressi

122 Hepatitis B virus (HBV) genotype C causes prolonged chronic infect

123 The hepatitis B virus (HBV) has been described as stealth virus subver

124 Reactivation of hepatitis B virus (HBV) has been reported in hepatitis C virus-inf

125 HBV-driven tumor growth.IMPORTANCE Hepatitis B virus (HBV) HBx protein plays a critical role in viral

126 Hepatitis B virus (HBV) immunization has been effectively preventi

127 linicians should vaccinate against hepatitis B virus (HBV) in all unvaccinated adults (including preg

128 The basis for the persistence of hepatitis B virus (HBV) in hepatocytes, even in the presence of av

129 e introduction of immunisation for hepatitis B virus (HBV) in the 1990s, HBV-related morbidity and mo

130 Hepatitis B virus (HBV) infection afflicts millions worldwide, cau

131 atment-naive patients with chronic hepatitis B virus (HBV) infection but not in treatment-experienced

132 ed therapeutic ARC-520 for chronic hepatitis B virus (HBV) infection consists of a melittin-derived p

133 ntion and treatment interventions, hepatitis B virus (HBV) infection continues to cause nearly 1 mill

134 t are the screening guidelines for hepatitis B virus (HBV) infection for asymptomatic, nonpregnant ad

135 tients with HBeAg-negative chronic hepatitis B virus (HBV) infection in a non-inferiority study.

136 tients with HBeAg-positive chronic hepatitis B virus (HBV) infection in a non-inferiority study.

137 unds.The lack of models that mimic hepatitis B virus (HBV) infection in a physiologically relevant co

138 However, studies of hepatitis B virus (HBV) infection in chimpanzees have indicated th

139 Despite the high burden of hepatitis B virus (HBV) infection in sub-Saharan Africa, absence o

140 The number of persons with chronic hepatitis B virus (HBV) infection in the United States is affected

141 the prevalence and distribution of hepatitis B virus (HBV) infection in U.S. Hispanics/Latinos.

142 Chronic hepatitis B virus (HBV) infection is a global public health issue.

143 Chronic hepatitis B virus (HBV) infection is a global public health proble

144 Chronic hepatitis B virus (HBV) infection is a major factor in hepatocellu

145 Chronic hepatitis B virus (HBV) infection is a major risk factor for devel

146 Chronic hepatitis B virus (HBV) infection is a major risk factor for hepat

147 Hepatitis B virus (HBV) infection is a serious public health probl

148 Persistent hepatitis B virus (HBV) infection is established by the formation

149 Chronic hepatitis B virus (HBV) infection is estimated to affect >350 mill

150 Chronic Hepatitis B Virus (HBV) infection is generally not curable with cu

151 Hepatitis B virus (HBV) infection is more common in African Americ

152 Chronic hepatitis B virus (HBV) infection is partly responsible for hepati

153 A hallmark of chronic hepatitis B virus (HBV) infection is the functional impairment and

154 Chronic hepatitis B virus (HBV) infection often develop into cirrhosis, an

155 hosis due to other causes, such as hepatitis B virus (HBV) infection or alcohol, remains unknown.

156 eneous clinical courses of chronic hepatitis B virus (HBV) infection reflect the complex host-virus i

157 Chronic hepatitis B virus (HBV) infection remains the most common risk fac

158 Hepatitis B virus (HBV) infection represents a significant public

159 Vaccine failure with chronic hepatitis B virus (HBV) infection still develops in children after

160 Patients with resolved hepatitis B virus (HBV) infection who are treated for hematologica

161 can occur with active or resolved hepatitis B virus (HBV) infection with a clinical spectrum that ra

162 among the highest rates of chronic hepatitis B virus (HBV) infection worldwide, but little is known a

163 C virus (HCV) infection, 17.9% had hepatitis B virus (HBV) infection, and 2.2% had both.

164 e can reduce the burden of chronic hepatitis B virus (HBV) infection.

165 particularly promising for chronic hepatitis B virus (HBV) infection.

166 with current or prior exposure to hepatitis B virus (HBV) infection.

167 ic risk factors, for patients with hepatitis B virus (HBV) infection.

168 CC), often associated with chronic hepatitis B virus (HBV) infection.

169 surface antigen (HBsAg) in chronic hepatitis B virus (HBV) infections of China remains unclear.

170 BACKGROUND & AIMS: Hepatitis B virus (HBV) infects hepatocytes, but the mechanisms of

171 Hepatitis B virus (HBV) is a major global health concern, and the

172 Hepatitis B virus (HBV) is a major human pathogen, and about one t

173 competent viral capsids.IMPORTANCE Hepatitis B virus (HBV) is a major human pathogen, and novel targe

174 Hepatitis B virus (HBV) is an important global human pathogen and

175 atitis B (CHB), failure to control hepatitis B virus (HBV) is associated with T cell dysfunction.

176 Hepatitis B virus (HBV) is endemic in sub-Saharan Africa, and desp

177 Hepatitis B virus (HBV) modulates microRNA (miRNA) expression to s

178 examined the associations between hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and t

179 ses of which are related to either hepatitis B virus (HBV) or hepatitis C virus (HCV).

180 ve (HBV DNA <20,000 IU/mL) chronic hepatitis B virus (HBV) patients.

181 and interleukin 10) to overlapping hepatitis B virus (HBV) peptides (preS, S, preC, core, and reverse

182 Chronic infection with hepatitis B virus (HBV) progresses through different phases.

183 and defines the clinical value of hepatitis B virus (HBV) quasispecies with reverse transcriptase an

184 Reports were published recently on hepatitis B virus (HBV) reactivation (HBV-R) in patients with HBV-

185 Hepatitis B virus (HBV) reactivation has been reported in HBV-HCV-

186 Hepatitis B virus (HBV) reactivation in hepatitis B surface antige

187 motherapy regimens pose a risk for hepatitis B virus (HBV) reactivation, but screening and antiviral

188 Immunosuppressants can induce hepatitis B virus (HBV) reactivation; however, informative data ab

189 sporting polypeptide (NTCP) as the hepatitis B virus (HBV) receptor enabled researchers to create hep

190 (HBIg) is effective in preventing hepatitis B virus (HBV) recurrence after liver transplantation, bu

191 l component of prophylaxis against hepatitis B virus (HBV) recurrence in liver transplantation (LT) r

192 er-to-child transmission (MTCT) of hepatitis B virus (HBV) remains the major risk factor for chronic

193 echanisms for achieving an optimal hepatitis B virus (HBV) replication have been largely unknown.

194 Hepatitis B Virus (HBV) replication in hepatocytes is restricted b

195 To understand subcellular sites of hepatitis B virus (HBV) replication, we visualized core (Cp), poly

196 dNTPs) are essential for efficient hepatitis B virus (HBV) replication.

197 tent or chronic infection with the hepatitis B virus (HBV) represents one of the most common viral di

198 ding to hepatitis C virus (HCV) or hepatitis B virus (HBV) status.

199 , despite loss of antibody against hepatitis B virus (HBV) surface antigen (anti-HBs), is undetermine

200 Humans vaccinated with hepatitis B virus (HBV) surface antigen (HBsAg) sometimes develop

201 REP 2139 clears circulating hepatitis B virus (HBV) surface antigen (HBsAg), enhancing the res

202 New hepatitis B virus (HBV) therapies are expected to have breakthroug

203 Despite immunoprophylaxis, hepatitis B virus (HBV) transmission in highly viremic mothers rem

204 of strategies to prevent perinatal hepatitis B virus (HBV) transmission in the United States is neede

205 Here, the CTD from the human hepatitis B virus (HBV) was found to be dephosphorylated in associ

206 us estimates of the burden of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) among people

207 uman immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV).

208 dults wait-listed for LT from HCV, hepatitis B virus (HBV), and nonalcoholic steatohepatitis (NASH) w

209 y of HIV, hepatitis C virus (HCV), hepatitis B virus (HBV), and tuberculosis in prisoners.

210 Hepatitis B virus (HBV), belonging to Hepadnaviridae family, remai

211 he transcriptional template of the hepatitis B virus (HBV), covalently closed circular DNA (cccDNA),

212 ta virus (HDV), a satellite of the hepatitis B virus (HBV), increases viral liver disease severity.

213 ents with hepatitis C virus (HCV), hepatitis B virus (HBV), NAFLD, and alcoholic liver diseases; (2)

214 ons by either hepatitis A virus or hepatitis B virus (HBV), or a noninfectious cause for their ALF.

215 erse transcriptase protein (RT) of hepatitis B virus (HBV), sampled from patients with rapid or slow

216 Here, using mutational analyses of hepatitis B virus (HBV), we found that Hsp90 stimulates deaminatio

217 nces of chronic hepatitis B (CHB), Hepatitis B virus (HBV)-associated cirrhosis and HBV-associated ca

218 Hepatitis B virus (HBV)-encoded X protein (HBx) plays a critical r

219 We have sampled healthy and hepatitis B virus (HBV)-infected human livers to probe for a subse

220 e of Mg(2+) homeostasis on chronic hepatitis B virus (HBV)-infected natural killer (NK) and CD8(+) T

221 In this study hepatitis B virus (HBV)-naive older adults received three vaccines

222 Activated and hepatitis B virus (HBV)-specific T cells, particularly the CD4 fra

223 HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV).

224 irus (HDV) is a satellite virus of hepatitis B virus (HBV).

225 with acute, resolved, and chronic hepatitis B virus (HBV)infection but might also signify occult HBV

226 in HCV+ liver biopsies compared to hepatitis B virus (HBV+) and uninfected samples.

227 atitis C virus [HCV] and five with hepatitis B virus [HBV]) of 600 HIV-infected patients who had unde

228 Hepatitis B viruses (HBVs), which are enveloped viruses with rever

229 Hepadnaviruses (hepatitis B viruses [HBVs]) are the only animal viruses that repli

230 d to the conserved stalk domain of influenza B virus hemagglutinin.

231 Treatment of hepatitis B virus, hepatitis C virus, and acute T cell-mediated re

232 f major human pathogens, including hepatitis B virus, hepatitis C virus, and malaria.

233 n the sera from patients with AIH, hepatitis B virus, hepatitis C virus, and nonalcoholic steatohepat

234 The prevalence of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis are higher

235 Influenza A virus (IAV) and influenza B virus (IBV) cause substantial morbidity and mortality

236 Influenza B virus (IBV) causes annual influenza epidemics around t

237 Influenza B virus (IBV) is considered a major human pathogen, resp

238 tis B virus, and rescues wild-type hepatitis B virus in a DDB1-knockdown background.

239 rase chain reaction-confirmed influenza A or B virus in all participants (vaccinated children and per

240 ts a check on replication of influenza A and B viruses in cell culture but does not inhibit Sendai vi

241 s confirmed in HEV gt1, but not in Hepatitis B Virus infected animals.

242 ced liver injury DILI (22%), acute hepatitis B virus infection (12%), autoimmune hepatitis (12%), and

243 nfection (41%), alcohol (39%), and hepatitis B virus infection (22%) the commonest etiologies present

244 nes recommend treatment of chronic hepatitis B virus infection (CHB) with the nucleos(t)ide analogs (

245 ectional analysis of prevalence of hepatitis B virus infection (HBV) among rural couples was conducte

246 za A(H1N1) virus (A[H1N1]pdm09) or influenza B virus infection (P = .2 and .4, respectively).

247 Chronic hepatitis B virus infection is a leading cause of cirrhosis and li

248 mmunocompromised murine models for influenza B virus infection that will facilitate evaluations of th

249 er, and hepatitis C virus (HCV) or hepatitis B virus infection) with non-HIV-infected controls (1:3 r

250 D) protected these nectin-bearing cells from B virus infection, and a gD-negative recombinant B virus

251 mmunocompromised murine models for influenza B virus infection, which we subsequently used to study p

252 is an effective measure to prevent hepatitis B virus infection.

253 t provide cross-protection against influenza B virus infection.

254 nfection are at increased risk for hepatitis B virus infection.

255 trategy to broadly protect against influenza B virus infection.IMPORTANCE While current influenza vir

256 ty; 12.5% (95% CI: 10.6-14.3%) for hepatitis B virus infection; 29.1% (95% CI: 23.6-34.5%) for hepati

257 r mL); HLA-B*5701-negative; had no hepatitis B virus infection; screening genotypes showing sensitivi

258 vir is less effective for treating influenza B virus infections than for treating influenza A virus i

259 However, hepatitis B virus inhibited the AIM2 inflammasome by reducing the

260 For the discovery of hepatitis B virus integration sites from probe capture data, the v

261 Hepatitis B virus is one of the smallest human pathogens, encoded

262 nd long-lasting protection against influenza B viruses is therefore urgently needed.

263 re we investigated the abilities of clinical B virus isolates to use entry receptors of herpes simple

264 We observed that the infectivity of B virus isolates with a single amino acid substitution (

265 Similar to a B virus lab strain, B virus clinical strains can effecti

266 B virus (Macacine herpesvirus 1) can cause deadly zoonot

267 Two closely related clade B viruses, Machupo virus (MACV) and Junin virus (JUNV),

268 cted patients, 25 individuals with hepatitis B virus monoinfection and 18 healthy controls.

269 Formation of the hepatitis B virus nucleocapsid is an essential step in the viral l

270 Chronic hepatitis B virus or hepatitis C co-infection was allowed.

271 Patients with co-infection (hepatitis B virus or HIV infection), evidence of decompensated liv

272 Other viruses, such as hepatitis B virus or human herpesvirus 8 (HHV-8), establish persis

273 y weaker NAb activity against tier 1 subtype B viruses (P = 0.003 for SF-162 and P = 0.017 for NL4-3)

274 fluenza A(H1N1)pdm09 (p=0.01), and influenza B viruses (p=0.04).

275 fluenza A(H1N1)pdm09 (p=0.01), and influenza B viruses (p=0.04).

276 edium (80 influenza A virus and 16 influenza B virus positive) from both adult and pediatric patients

277 ted on thousands of seasonal influenza A and B virus-positive specimens using multiple next-generatio

278 tes several direct target genes of hepatitis B virus protein X (HBx), a viral co-factor.

279 Hepatitis B virus reactivation (HBVr) is an important complication

280 Hepatitis B virus reactivation is a newly identified safety concer

281 Hepatitis B virus reactivation, defined as an abrupt increase in H

282 and H5N1 and with H1N1, H3N2, and influenza B viruses, respectively.

283 of T cells engineered to express a hepatitis B virus-specific (HBV-specific) T cell receptor (TCR) ma

284 able on covariates, such as HIV or hepatitis B virus status, for subgroup analyses.

285 er-to-child transmission (MTCT) of Hepatitis B Virus still occurs in approximately 2-5% of HBsAg posi

286 ivary IgA to influenza A(H3N2) and influenza B virus strains as early as 14 days after vaccination bu

287 to detect, type and subtype influenza A and B virus strains directly from clinical samples in a sing

288 nal amplifier for determination of hepatitis B virus surface antigen (HBsAg).

289 Roche Diagnostics]) with the influenza A and B virus test components of the FilmArray respiratory pan

290 We studied three influenza B viruses that represent both the Yamagata (B/Massachuse

291 In hepatitis B virus, this is manifested as a virion where the envelo

292 The ability of B virus to enter cells of a human host by using a combin

293 are largely responsible for the inability of B virus to utilize HVEM for entry.

294 achromosomal reporter genes and on hepatitis B virus transcription.

295 o comparing LAIV with IIV for influenza A or B virus was 1.03 (95% CI, 0.85 to 1.24).

296 (1054 [84%] of 1251 patients), and hepatitis B virus was the leading cause in the other African count

297 d deaths are due to infection with influenza B viruses, which co-circulate in the human population as

298 or influenza A virus and 93.3% for influenza B virus, with specificities of 100% for both viruses.

299 The hepatitis B virus deploys the hepatitis B virus X protein (HBx) as a suppressor of host defenses

300 CC that spontaneously developed in hepatitis B virus X protein (HBx) transgenic mice.